3-Deazaneplanocin A is a Promising Therapeutic Agent for Ovarian Cancer Cells

Shen, Liang; Cui, Jing; Pang, Yingxin; Ma, Yonggang; Liu, Peishu

doi:10.7314/apjcp.2013.14.5.2915

Cited by 5 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another inhibitor, 3-Deazaneplanocin A (DZNep), which inhibits S-adenosylhomocysteine hydrolase is shown to deplete cellular levels of EZH2 in breast and colorectal cancer cells [137]. Treatment of A2780 OvCa cells with DZNep increased apoptosis as measured by Annexin-V and 7-AAD staining [138].…”

Section: Epigenetic Modifications and Their Role In Ovca Apoptosismentioning

confidence: 99%

Understanding and Targeting Apoptotic Pathways in Ovarian Cancer

Al-Alem

Baker

Pandya

et al. 2019

Cancers

View full text Add to dashboard Cite

Ovarian cancer cells evade the immune system as well as chemotherapeutic and/or biologic treatments through inherent or acquired mechanisms of survival and drug resistance. Depending on the cell type and the stimuli, this threshold can range from external forces such as blunt trauma to programmed processes such as apoptosis, autophagy, or necroptosis. This review focuses on apoptosis, which is one form of programmed cell death. It highlights the multiple signaling pathways that promote or inhibit apoptosis and reviews current clinical therapies that target apoptotic pathways in ovarian cancer.

show abstract

Section: Epigenetic Modifications and Their Role In Ovca Apoptosismentioning

confidence: 99%

Understanding and Targeting Apoptotic Pathways in Ovarian Cancer

Al-Alem

Baker

Pandya

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…Currently, several inhibitors of HKMTs have been developed. 3-Deazaneplanocin A (DZNEP), the first indirect inhibitor of EZH2, was reported to be a promising cancer-fighting agent for malignant ovarian tumor, with potential to reduce proliferation, induce apoptosis, and inhibit metastasis [ 209 ]. More interestingly, Bitler et al demonstrated that EZH2 inhibitor, GSK126, acts in a synthetic lethal manner in ARID1A-mutated ovarian cancer cells and that ARID1A mutational status correlated with response to the EZH2 inhibitor [ 210 ].…”

Section: Clinical Applicationsmentioning

confidence: 99%

Epigenetics in ovarian cancer: premise, properties, and perspectives

Yang

Zhou

et al. 2018

Mol Cancer

View full text Add to dashboard Cite

Malignant ovarian tumors bear the highest mortality rate among all gynecological cancers. Both late tumor diagnosis and tolerance to available chemical therapy increase patient mortality. Therefore, it is both urgent and important to identify biomarkers facilitating early identification and novel agents preventing recurrence. Accumulating evidence demonstrates that epigenetic aberrations (particularly histone modifications) are crucial in tumor initiation and development. Histone acetylation and methylation are respectively regulated by acetyltransferases-deacetylases and methyltransferases-demethylases, both of which are implicated in ovarian cancer pathogenesis. In this review, we summarize the most recent discoveries pertaining to ovarian cancer development arising from the imbalance of histone acetylation and methylation, and provide insight into novel therapeutic interventions for the treatment of ovarian carcinoma.

show abstract

“…Among current HDAC inhibitors, suberoylanilide hydroxamic acid, valproic acid, and romidepsin have been tested in ovarian cancer as single agents or in combination with other drugs. The use of therapy targeting modified histones and the enzymes regulating them is quite promising in ovarian cancer [141][142][143][144]. However, nowadays, robust clinical trials are unavailable, making it difficult to ascertain whether this treatment offers beneficial clinical outcomes with tolerated side-effect profiles.…”

Section: Histone Modifications and Involved Enzymesmentioning

confidence: 99%

Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer

Sassu¹,

Palaia²,

Boccia³

et al. 2021

IJMS

View full text Add to dashboard Cite

Ovarian cancer (OC) is the second most common cause of death in women with gynecological cancer. Considering the poor prognosis, particularly in the case of platinum-resistant (PtR) disease, a huge effort was made to define new biomarkers able to help physicians in approaching and treating these challenging patients. Currently, most data can be obtained from tumor biopsy samples, but this is not always available and implies a surgical procedure. On the other hand, circulating biomarkers are detected with non-invasive methods, although this might require expensive techniques. Given the fervent hope in their value, here we focused on the most studied circulating biomarkers that could play a role in PtR OC.

show abstract

3-Deazaneplanocin A is a Promising Therapeutic Agent for Ovarian Cancer Cells

Cited by 5 publications

References 18 publications

Understanding and Targeting Apoptotic Pathways in Ovarian Cancer

Understanding and Targeting Apoptotic Pathways in Ovarian Cancer

Epigenetics in ovarian cancer: premise, properties, and perspectives

Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer

Contact Info

Product

Resources

About